Navidea Biopharmaceuticals, Inc.
NAVBDelisted Jan 16, 2024- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000810509
Navidea Biopharmaceuticals, Inc. was delisted on Jan 16, 2024; its insiders filed their last Form 4 on Dec 5, 2023; 24 institutions reported holding it in 13F filings for Q3 2023, worth $225.8K in total; no superinvestor held it.
Q4 2023 vs. Q3 2023
How the institutions holding Navidea Biopharmaceuticals, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Of which not filed for Q4 2023 | Q4 2023 | Change |
|---|---|---|---|---|
| Holders | 24 | 1 | 4 | −19 |
| Shares | 2.52M | 10.0K | 11.2K | −2.49M (−99.6%) |
| Value | $225.8K | $900 | $469 | −$224.4K (−99.8%) |
1 institution that held it in Q3 2023 haven't filed for Q4 2023 yet. Not filing isn't selling, so the changes leave them out.
New holders (2)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Baader Bank INC | 10,630 | $435 | 0.00% |
| Advisory Services Network, LLC | 250 | $14 | 0.00% |
Sold out (21)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Allred Capital Management, LLC | 466,688 | $41.9K |
| State Street Corp | 412,743 | $37.0K |
| Geode Capital Management, LLC | 368,830 | $33.1K |
| Virtu Financial LLC | 333,069 | $30.0K |
| Vanguard Group Inc | 276,491 | $24.8K |
| Warberg Asset Management LLC | 194,997 | $17.5K |
| UBS Group AG | 149,612 | $13.5K |
| BlackRock Inc. | 113,030 | $10.1K |
| Level Four Advisory Services, LLC | 55,555 | $4.98K |
| Boothbay Fund Management, LLC | 40,000 | $3.59K |
| Northern Trust Corp | 39,414 | $3.54K |
| Two Sigma Securities, LLC | 31,553 | $2.83K |
| Tower Research Capital LLC (TRC) | 8,937 | $804 |
| Wells Fargo & Company | 5,632 | $504 |
| Morgan Stanley | 4,416 | $396 |
| Bank of America Corp | 1,604 | $143 |
| JPMorgan Chase & Co | 1,300 | $116 |
| Sound Income Strategies, LLC | 599 | $54 |
| GWM Advisors LLC | 412 | $36 |
| Group One Trading, L.P. | 300 | $27 |
| Kelly Financial Services LLC | 50 | $4 |
Not filed for Q4 2023 yet (1)
Institutions that held Navidea Biopharmaceuticals, Inc. at the end of Q3 2023 and haven't filed a 13F for Q4 2023. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Pathstone Family Office, LLC | 10,043 | $900 |